BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19151)

  • 21. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
    Kickinger W; Ritschl P; Kotz R
    Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
    Homesley HD
    J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of a massive dosage of methotrexate and leucovorin rescue therapy on acute leukemia and malignant lymphoma].
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):421-32. PubMed ID: 6764106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose methotrexate with leucovorin rescue, vinblastine, and bleomycin with or without tamoxifen in metastatic renal cell carcinoma.
    Bell DR; Aroney RS; Fisher RJ; Levi JA
    Cancer Treat Rep; 1984 Apr; 68(4):587-90. PubMed ID: 6201268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases.
    Lehane DE; Lane M; Tranum B; Costanzi J; Padilla F
    Cancer Treat Rep; 1977 Aug; 61(5):889-91. PubMed ID: 329982
    [No Abstract]   [Full Text] [Related]  

  • 28. [High dose of methotrexate-leucovorin treatment in advanced non-Hodgkin's lymphoma].
    Kawarabayashi K; Yoshikawa T; Sannomiya Y; Hashimoto K; Araki J; Park K; Tatumi Y; Kamitani T; Im T; Tatumi N
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2493-9. PubMed ID: 6606395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
    Von Hoff DD; Penta JS; Helman LJ; Slavik M
    Cancer Treat Rep; 1977 Jul; 61(4):745-8. PubMed ID: 301783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
    Wiemann MC; Cummings FJ; Kaplan HG; Spremulli EN; Doolittle CH; Calabresi P
    Cancer Res; 1982 Sep; 42(9):3896-900. PubMed ID: 6980707
    [No Abstract]   [Full Text] [Related]  

  • 31. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
    Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
    Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
    Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
    Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms.
    Goldstein DP; Goldstein PR; Bottomley P; Osathanondh R; Marean AR
    Obstet Gynecol; 1976 Sep; 48(3):321-3. PubMed ID: 181702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experiences with enterally and parenterally applied leucovorin following therapy with high doses of methotrexate in malignant tumors (author's transl)].
    Vahrson H; Gorges K
    Med Klin; 1976 Oct; 71(41):1720-3. PubMed ID: 1086422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate therapy and nitrous oxide anesthesia.
    Ueland PM; Refsum H; Wesenberg F; Kvinnsland S
    N Engl J Med; 1986 Jun; 314(23):1514. PubMed ID: 3486365
    [No Abstract]   [Full Text] [Related]  

  • 37. Methotrexate in the treatment of psoriasis.
    Med Lett Drugs Ther; 1972 Jun; 14(12):41-2. PubMed ID: 4567562
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
    Hum M; Holcenberg JS; Tkaczewski I; Weaver JW; Wilson J; Kamen BA
    Clin Cancer Res; 1998 Dec; 4(12):2981-4. PubMed ID: 9865909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.